- Home
- DOMH vs ENSC Comparison
DOMH vs ENSC Comparison
Compare DOMH & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- ENSC
- Stock Information
- Founded
- DOMH 1967
- ENSC 2003
- Country
- DOMH United States
- ENSC United States
- Employees
- DOMH N/A
- ENSC N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- ENSC Health Care
- Exchange
- DOMH Nasdaq
- ENSC Nasdaq
- Market Cap
- DOMH 83.3M
- ENSC 4.9M
- IPO Year
- DOMH N/A
- ENSC N/A
- Fundamental
- Price
- DOMH $5.44
- ENSC $2.23
- Analyst Decision
- DOMH
- ENSC
- Analyst Count
- DOMH 0
- ENSC 0
- Target Price
- DOMH N/A
- ENSC N/A
- AVG Volume (30 Days)
- DOMH 312.8K
- ENSC 228.7K
- Earning Date
- DOMH 08-07-2025
- ENSC 08-13-2025
- Dividend Yield
- DOMH 5.84%
- ENSC N/A
- EPS Growth
- DOMH N/A
- ENSC N/A
- EPS
- DOMH N/A
- ENSC N/A
- Revenue
- DOMH $24,891,000.00
- ENSC $6,224,081.00
- Revenue This Year
- DOMH N/A
- ENSC N/A
- Revenue Next Year
- DOMH N/A
- ENSC $1,381.48
- P/E Ratio
- DOMH N/A
- ENSC N/A
- Revenue Growth
- DOMH 630.80
- ENSC 256.35
- 52 Week Low
- DOMH $0.83
- ENSC $1.62
- 52 Week High
- DOMH $13.58
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- DOMH 51.73
- ENSC 49.53
- Support Level
- DOMH $5.47
- ENSC $2.02
- Resistance Level
- DOMH $6.08
- ENSC $2.30
- Average True Range (ATR)
- DOMH 0.55
- ENSC 0.14
- MACD
- DOMH 0.02
- ENSC 0.02
- Stochastic Oscillator
- DOMH 35.76
- ENSC 43.40
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.